Piermont Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Piermont Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-172,980	Closed	-$3.1M	–	268
2017 Q4	$3.1M	Sell	172,980 -5,590	-3%	-$68.8K	1.02%	10
2017 Q3	$2.11M	Buy	178,570 +122,463	+218%	+$1.37M	0.7%	69
2017 Q2	$589K	Sell	56,107 -9,852	-15%	-$100K	0.17%	218
2017 Q1	$726K	Hold	65,959	–	–	0.17%	197
2016 Q4	$894K	Sell	65,959 -1,310	-2%	-$18.3K	0.2%	173
2016 Q3	$828K	Buy	67,269 +5,770	+9%	+$68K	0.2%	182
2016 Q2	$675K	Buy	61,499 +29,629	+93%	+$332K	0.17%	204
2016 Q1	$348K	Buy	31,870 +1,170	+4%	+$14.8K	0.11%	194
2015 Q4	$531K	Sell	30,700 -2,060	-6%	-$36.9K	0.17%	136
2015 Q3	$651K	Hold	32,760	–	–	0.21%	112
2015 Q2	$538K	Hold	32,760	–	–	0.16%	156
2015 Q1	$510K	Buy	+32,760	New	+$508K	0.16%	172

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Piermont Capital Management's SCMP Position: Q1 2018 in Review

Piermont Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 172,980 shares — an estimated $3.1M sold.

Piermont Capital Management first reported a position in SCMP in Q1 2015 and held it in 12 quarters. The position peaked at $3.1M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Piermont Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Piermont Capital Management sold 172,980 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $3.1M.
Piermont Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 12 quarters.
Piermont Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $3.1M in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Piermont Capital Management's 13F filing for Q1 2018, filed 9 May 2018.